Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × amivantamab × 1 year × Clear all

NCT02609776 2026-06-05

CHRYSALIS

Phase 1 Active not recruiting

751 enrolled 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05488314 2026-06-05

METalmark

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05498428 2026-06-05

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05908734 2026-06-05

PolyDamas

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-06-05

COCOON

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-06-05

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT07227025 2026-06-05

KaRAnaSa

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-06-02

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT07586202 2026-05-14

AmiNA

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT04077463 2026-05-08

Chrysalis-2

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04487080 2026-05-08

MARIPOSA

Phase 3 Active not recruiting

1,074 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04538664 2026-05-08

PAPILLON

Phase 3 Active not recruiting

308 enrolled 12 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04988295 2026-05-08

MARIPOSA-2

Phase 3 Active not recruiting

776 enrolled 13 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT05388669 2026-05-08

PALOMA-3

Phase 3 Active not recruiting

418 enrolled 16 charts

Carcinoma, Non-Small-Cell Lung

NCT06116682 2026-05-06

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06532032 2026-04-13

swalloWTail

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05801029 2026-03-20

OSTARA

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT06083857 2026-03-11

PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07392658 2026-02-06

AMICUTE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05845671 2026-01-14

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung